Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications

Bhilare, Neha V.; Shedge, Rushikesh; Tambe, Prashant M.; More, Ajinkya

doi:10.1007/s00044-024-03187-2

Med Chem Res

2024

DOI: 10.1007/s00044-024-03187-2

|View full text |Cite

Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications

Neha V. Bhilare,

Rushikesh Shedge,

Prashant M. Tambe

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Electroactive Molecularly Imprinted Polymer Nanoparticles (eMIPs) for Label‐free Detection of Glucose: Toward Wearable Monitoring

Garg,

Singla,

Kaur

et al. 2024

Small

View full text Add to dashboard Cite

The diagnosis of diabetes mellitus (DM) affecting 537 million adults worldwide relies on invasive and costly enzymatic methods that have limited stability. Electroactive polypyrrole (PPy)‐based molecularly imprinted polymer nanoparticles (eMIPs) have been developed that rival the affinity of enzymes whilst being low‐cost, highly robust, and facile to produce. By drop‐casting eMIPs onto low‐cost disposable screen‐printed electrodes (SPEs), sensors have been manufactured that can electrochemically detect glucose in a wide dynamic range (1 µm–10 mm) with a limit of detection (LOD) of 26 nm. The eMIPs sensors exhibit no cross reactivity to similar compounds and negligible glucose binding to non‐imprinted polymeric nanoparticles (eNIPs). Measurements of serum samples of diabetic patients demonstrate excellent correlation (>0.93) between these eMIPs sensor and the current gold standard Roche blood analyzer test. Finally, the eMIPs sensors are highly durable and reproducible (storage >12 months), showcasing excellent robustness and thermal and chemical stability. Proof‐of‐application is provided via measuring glucose using these eMIPs sensor in a two‐electrode configuration in spiked artificial interstitial fluid (AISF), highlighting its potential for non‐invasive wearable monitoring. Due to the versatility of the eMIPs that can be adapted to virtually any target, this platform technology holds high promise for sustainable healthcare applications via providing rapid detection, low‐cost, and inherent robustness.

show abstract

Electroactive Molecularly Imprinted Polymer Nanoparticles (eMIPs) for Label‐free Detection of Glucose: Toward Wearable Monitoring

Garg,

Singla,

Kaur

et al. 2024

Small

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications

Cited by 1 publication

References 72 publications

Electroactive Molecularly Imprinted Polymer Nanoparticles (eMIPs) for Label‐free Detection of Glucose: Toward Wearable Monitoring

Electroactive Molecularly Imprinted Polymer Nanoparticles (eMIPs) for Label‐free Detection of Glucose: Toward Wearable Monitoring

Contact Info

Product

Resources

About